

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|---|
| Name of entity | Sigma Healthcare Limited (" Sigma ") |
| ABN | 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------------|
| Name of Director | Danielle Di Pilla |
| Date of last notice | 30 May 2025 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| Date of change | 9 January 2026 |
| No. of securities held prior to change | <u>Direct interests</u> 31,401,068 ordinary shares <u>Indirect interests</u> 44,228,054 ordinary shares held through Di Pilla Investments Pty Ltd as trustee for the Di Pilla Family Trust (Danielle Di Pilla is the sole director and sole shareholder of Di Pilla Investments Ltd) |
| Class | Rights to acquire fully paid ordinary shares in Sigma granted under Sigma's 2025 Long Term Incentive Plan |
| Number acquired | 141,591 |
| Number disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | The rights were granted under Sigma's 2025 Long Term Incentive Plan approved at Sigma's 2025 AGM. The Rights are issued for nil consideration and represent part of the employee incentive scheme component for Ms Di Pilla. |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held after change | <u>Direct</u> 31,401,068 ordinary shares 141,591 2025 LTI Rights <u>Indirect</u> 44,228,054 ordinary shares through Di Pilla Investments Pty Ltd as trustee for the Di Pilla Family Trust (Danielle Di Pilla is the sole director and sole shareholder of Di Pilla Investments Ltd) |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issuance of performance rights under Sigma's 2025 Long Term Incentive Plan |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
|---|----|

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

+ See chapter 19 for defined terms.